Objectives: This study aims to investigate whether trimetazidine (TMZ) alone has a preventive effect on contrast-induced nephropathy (CIN) in patients with preserved kidney function who underwent angiographic procedures and the variables associated with CIN development. Patients and methods: Between June 2023 and September 2023, a total of 305 patients (199 males, 106 females; mean age: 60+/-10 years; range, 54 to 67 years) who underwent coronary angiographic procedures with diagnosed or suspected stable coronary artery disease and an estimated glomerular filtration rate (eGFR) of >60 mL/min/1.73 m2 were included. A total of 153 patients received TMZ (TMZ group), while 152 patients were nave to TMZ (non-TMZ group). Results: Ten patients (6.5%) in the non-TMZ group and nine patients (5.8%) in the TMZ group developed CIN within 48 to 72 h (p=0.801) after the procedures. The mean serum creatinine level increased from 0.84+/-0.1 mg/dL to 0.89+/-0.2 mg/dL in the non-TMZ group (p<0.001) and from 0.84+/-0.1 mg/dL to 0.88+/-0.2 mg/dL in the TMZ group (p=0.008). Multivariate logistic regression analysis revealed that only age (odds ratio [OR]: 1.10, 95% CI: 1.03-1.18, p=0.003) was an independent predictor of CIN. A cut-off value of 60 years (area under the curve [AUC]=0.785; sensitivity, 100%; specificity, 52%) predicted CIN development in the non-TMZ group, whereas it was 72.5 years (AUC=0.711; sensitivity, 55%; specificity, 90%) for the TMZ group. Conclusion: Our study results suggest that the use of TMZ may be beneficial on CIN in elderly patients undergoing coronary angiographic procedures, even if the eGFR is >=60 mL/min/1.73 m2.
